JPMorgan names CVS a top pick as turnaround gains traction. Argus trims price target to $90 from $91 but maintains Buy rating. Shares fell 15% after CMS proposed flat Medicare Advantage rates for 2027. CVS announces changes to preferred drug lists to cut prescription costs by over 50%.

CVS plans to replace certain bone disease treatments with lower-cost alternatives, expecting to save customers over $1.5 billion. The company’s diversified business is seen as better positioned to handle potential impact of Medicare Advantage reimbursement rate proposal compared to companies relying solely on health insurance.

CVS Health Corporation operates as a health solutions company with various offerings in health insurance, pharmacy services, and retail pharmacy operations. While CVS presents investment potential, some AI stocks are believed to offer greater upside potential and less downside risk. For an undervalued AI stock with potential benefits from Trump-era tariffs and onshoring trend, check out the report on the best short-term AI stock.

Read more at Yahoo Finance: CVS Health Corporation (CVS) Under Pressure From Medicare Proposal, Argus Holds Positive View